

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

Claims 1-21 (canceled)

22. (currently amended) An immunogenic composition, wherein the composition is
~~Immunogenic compositions, characterized in that they are~~ created from preparations
obtained by:

- (a) incubation of first cells~~means~~ expressing the target receptor(s) of an infectious pathogenic agent, causing infections in a mammal by bonding and then fusion with target cells, with second cells~~means~~ expressing at least the regions of the infectious pathogenic agent recognizing the said target receptor(s)~~targets~~ under conditions enabling interaction of said~~the~~ first cells and said second cells~~means~~ so as to form a complex, this incubation step being done with different intervals in order to produce complexes corresponding to different fusion stages, and
- (b) putting the complexes formed into contact with a binding agent for different intervals, in order to bind complexes with different exposures and conformations of epitopes against which antibodies are to be formed, the said first cells and said second cells~~means~~ being tolerated by mammals.

23. (currently amended) The composition of~~Compositions according to~~ claim 22,
wherein said~~characterized in that the~~ first cells~~means~~ are autologous mammalian
~~mammal~~ cells.

24. (currently amended) The composition of~~Compositions according to~~ claim 22,
wherein said~~characterized in that the~~ first cells~~are transformed with~~~~means~~~~are~~ vectors
comprising genes expressing the target receptor(s).

Claim 25 (canceled)

26. (currently amended) The composition of~~Compositions according to~~ claim 22, wherein said ~~characterized in that the second~~ cells are transformed with vectors ~~means are previously transformed cells with a vector~~ carrying at least one bonding region to at least one receptor.

27. (currently amended) The composition of~~Compositions according to~~ claim 22, wherein said ~~characterized in that the second~~ cells are transformed with ~~means are made from~~ viral vectors carrying at least one bonding region to a target receptor.

28. (currently amended) The composition of~~Compositions according to~~ claim 22, wherein said ~~characterized in that the second~~ cells ~~means used~~ are infected cells that produce infectious pathogenic agents or are composed of infectious pathogenic agents.

29. (currently amended) The composition of~~Compositions according to~~ claim 22, wherein ~~characterized in that the said~~ infectious pathogenic agent is a virus ~~agents are viruses~~.

30. (currently amended) The composition of~~Compositions according to~~ claim 29, wherein said ~~characterized in that the~~ pathogenic agent is HIV.

31. (currently amended) The composition of~~Compositions according to~~ claim 22, wherein ~~characterized in that the said~~ preparations are obtained by incubation of first cells ~~means~~ expressing the CD4 receptor and/or HIV co-receptors with second cells ~~means~~ expressing at least the preserved regions in gp120 or gp160 envelope proteins.

32. (currently amended) The composition of~~Compositions according to~~ claim 31, wherein said ~~characterized in that the first~~ cells ~~are means used are composed of~~ autologous mammalian ~~cells of mammals~~ stimulated so as to express the CD4 receptor and/or HIV co-receptors, in a sufficient quantity for the required interaction.

33. (currently amended) The composition of~~Compositions according to~~ claim 31, wherein said ~~characterized in that the first~~ cells are transformed with~~means are~~ viral vectors comprising genes expressing CD4 and/or HIV co-receptors.

Claims 34 (canceled)

35. (currently amended) The composition of~~Compositions according to~~ claim 31, wherein said ~~characterized in that the second~~ cells are transformed with viral vectors~~means are composed of previously transformed cells with a viral vector~~ comprising at least regions of HIV-1 gp120 or HIV-1 gp160 envelope proteins, ~~or are composed of such viral vectors.~~

36. (currently amended) The composition of~~Compositions according to~~ claim 31, wherein said ~~characterized in that the second~~ cells~~means~~ are infected cells producing HIV or are composed of the HIV virus itself.

37. (currently amended) The composition of~~Compositions according to~~ claim 31, wherein said ~~characterized in that the second~~ cells express~~means are composed of~~ HIV-1 gp120 or HIV-1 gp160 envelope proteins in natural or recombining form.

38. (currently amended) The composition of~~Compositions according to~~ claim 31, wherein ~~characterized in that~~ one of the co-receptors of HIV is replaced by a monoclonal antibody directed to a region of gp120 which binds to HIV-1 co-receptors.

Claim 39 (canceled)

40. (currently amended) The composition of~~Compositions according to~~ claim 22, wherein said ~~characterized in that the~~ preparations are fixed with aldidrithiol-2 after incubation.

41. (currently amended) An isolated serum or antibody formed against the ~~[[a]]~~
composition of ~~according to~~ claim 22.

42. (currently amended) The composition of ~~Compositions according to~~ claim 22, further
comprising an inert vehicle acceptable for administration to a mammal, and optionally
with an additive.

43. (currently amended) The composition of ~~Compositions according to~~ claim 24,
wherein said ~~characterized in that the~~ vectors are viral vectors.

44. (currently amended) The composition of ~~Compositions according to~~ claim 28,
wherein said infectious ~~characterized in that the~~ pathogenic agents are selected from
the group consisting of a retrovirus, a bacteria, a mycobacteria, and a parasite.

45. (withdrawn/currently amended) The composition of ~~Compositions according to~~ claim
28, wherein said infectious ~~characterized in that the~~ pathogenic agents are selected
from the group consisting of a *Plasmodium sp.*, a *Leishmania sp.*, *Trypanosoma cruzi*
and *Trypanosoma brucei*.

46. (withdrawn/currently amended) The composition of ~~Compositions according to~~ claim
23, wherein said ~~characterized in that the first cells means~~ are healthy human cells
taken from a patient to be vaccinated.

47. (currently amended) The composition of ~~Compositions according to~~ claim 33,
wherein the viral vectors are ~~a baculoviruses or the Semliki forest viruses~~.

48. (withdrawn/currently amended) The composition of ~~Compositions according to~~ claim
31, wherein said ~~characterized in that the first cells means~~ are yeast expressing CD4
and/or HIV co-receptors at their surface.

49. (withdrawn/currently amended) ~~The composition of~~ Compositions according to claim 48, wherein said yeast are ~~a~~ Saccharomyces cerevisiae cerevi.

50. (new) An immunogenic composition for forming serum or antibody recognizing an infectious pathogenic agent, wherein the composition is created from preparations obtained by:

- (a) incubation of first cells expressing target receptor(s) of an infectious pathogenic agent, causing infections in a mammal by bonding and then fusion with target cells, with second cells expressing at least regions of the infectious pathogenic agent recognizing the said target receptor(s) under conditions enabling interaction of said first cells and said second cells so as to form a complex, this incubation step being done with different intervals in order to produce complexes corresponding to different fusion stages, and
- (b) putting the complexes formed into contact with a binding agent for different intervals, in order to bind complexes with different exposures and conformations of epitopes against which antibodies are to be formed, the said first cells and said second cells being tolerated by mammals.

51. (new) An isolated serum or antibody for recognition of an infectious pathogenic agent, wherein said serum or antibody is formed against the composition of claim 51.